Format

Send to

Choose Destination
See comment in PubMed Commons below
Obstet Gynecol. 1997 Apr;89(4):524-8.

Teratogenic study of doxycycline.

Author information

1
Department of Human Genetics and Teratology, National Institute of Hygiene--World Health Organization Collaborating Centre for the Community Control of Hereditary Diseases, Budapest, Hungary.

Abstract

OBJECTIVE:

To study the human teratogenic risk of doxycycline treatment during pregnancy.

METHODS:

Paired analysis of cases with congenital abnormalities and matched healthy controls was performed in the large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1992.

RESULTS:

Of 32,804 pregnant women who had infants with no defects in the study period (control group), 63 (0.19%) were treated with doxycycline. Of 18,515 pregnant women who had offspring with congenital abnormalities, 56 (0.30%) were treated with doxycycline, a rate that is higher than that of the control group (P = .01). However, the case-control pair analysis did not show a significantly higher rate of doxycycline treatment in the second and third months of gestation in any group of congenital abnormalities.

CONCLUSIONS:

Treatment with doxycycline during pregnancy presents very little if any teratogenic risk to the fetus. Thus, if doxycycline treatment is necessary during pregnancy, there would appear to be no contraindication.

PMID:
9083306
DOI:
10.1016/S0029-7844(97)00005-7
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center